UBS Remains a Hold on GlaxoSmithKline (GSK)
In a report released today, Matthew Weston from UBS maintained a Hold rating on GlaxoSmithKline, with a price target of p1,940.00.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Weston covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, Sanofi, and Roche Holding AG. According to TipRanks, Weston has an average return of 10.2% and a 69.00% success rate on recommended stocks.
In addition to UBS, GlaxoSmithKline also received a Hold from Berenberg Bank’s Kerry Holford in a report issued on March 26. However, on April 7, Barclays maintained a Sell rating on GlaxoSmithKline (LSE: GSK).
Based on GlaxoSmithKline’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p8.62 billion and a net profit of p636 million. In comparison, last year the company earned a revenue of p8.12 billion and had a net profit of p414 million
Based on the recent corporate insider activity of 324 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GSK in relation to earlier this year.
Read More on GB:GSK:
Disclaimer & DisclosureReport an Issue
- GSK Adds 330,000 Shares to Treasury in Ongoing Buyback Programme
- GSK pulls application for leucovorin calcium, WSJ reports
- GSK Discloses Executive Notional ADS Acquisition by US President
- GSK Expands Buyback With Treasury Share Purchase and Updates Voting Rights
- GSK announces China’s NMPA approved Exdensur as add-on therapy
